Cardiovascular Disease Risk Tests (for Kansas Only)

Coverage Summary

This UnitedHealthcare Community Plan policy applies to Kansas and addresses a range of proposed cardiovascular disease risk tests — including arterial compliance/waveform analysis, carotid intima-media thickness (CIMT), advanced lipoprotein analyses (e.g., Lp(a), particle subfractions, NMR), lipoprotein-associated phospholipase A2 (Lp-PLA2), endothelial function assessments (e.g., peripheral arterial tonometry or brachial artery ultrasound), and multiprotein biomarker panels with algorithmic risk scores — identified by specific CPT/PLA codes. These tests are evaluated as supplemental risk stratification tools beyond traditional risk factors and standard lipid profiles.

After review of the available evidence, these tests are considered unproven and not medically necessary for routine risk assessment or management because there is insufficient evidence that their use changes clinical management or improves patient outcomes; detailed criteria and rationale follow in the policy.

Key thresholds and policy takeaways

Lp(a) abnormal threshold≥ 50 mg/dL (≥ 125 nmol/L) considered high risk; ESC/EAS also cites > 50 mg/dL (≥ 105 nmol/L) as a risk modifier; ESC notes very high inherited Lp(a) > 180 mg/dL (> 430 nmol/L)

Lp(a) percentile risk strata>= 67th–89th percentile and > 90th percentile associated with increased risk (BiomarCaRE) — elevated HRs for MCEs and CVD

apoB thresholdsOptimal goals: < 90 mg/dL (increased risk), < 80 mg/dL (established ASCVD or diabetes + risk factor), < 70 mg/dL (extreme risk); elevated apoB ≥ 130 mg/dL is a risk‑enhancing factor

hs‑CRP threshold≥ 2.0 mg/L (ACC/AHA risk‑enhancing factor)

Primary hypertriglyceridemia≥ 175 mg/dL (nonfasting) (ACC/AHA risk‑enhancing factor)

NT‑proBNP / BNP thresholdsBNP ≥ 50 pg/mL or NT‑proBNP ≥ 125 pg/mL considered abnormal per ADA guidance for screening in asymptomatic adults with diabetes

ABI thresholdABI < 0.9 (risk‑enhancing factor)

Policy conclusionThese cardiovascular risk tests (arterial compliance/waveform analysis, CIMT, advanced lipoprotein testing including Lp(a)/apoB, Lp‑PLA2, endothelial function assessments, and specified multiprotein panels) are considered unproven and not medically necessary for routine use in Kansas due to insufficient evidence of clinical utility

State applicabilityThis policy applies only to the state of Kansas

Not Medically Necessary / Unproven Tests

Evidence Summary and Clinical Utility Conclusions

Cardiovascular risk tests such as arterial compliance, CIMT, advanced lipoprotein measurements, endothelial function assessments, and multiprotein biomarker panels have been proposed to enhance risk stratification beyond traditional risk factors, but the evidence of clinical utility and impact on management or outcomes is insufficient.

The policy therefore treats these modalities as unproven for routine clinical use and notes that, while associations with cardiovascular events exist for some markers (for example, Lp(a) and certain biomarker panels), high-quality prospective evidence demonstrating that testing leads to changes in clinical care that improve outcomes is lacking.

Study / Source	Key finding
Li et al. (2025) meta-analysis ePWV
Each 1‑m/s increase in ePWV associated with 36% higher cardiovascular events, 41% higher cardiovascular mortality, and 37% higher all‑cause mortality; no established cutoff or demonstrated clinical utility.
Sequí‑Domínguez et al. (2020) cfPWV
Pooled diagnostic OR 11.23 for cardiovascular mortality; AUROC ~0.75–0.78; incremental clinical utility not reported.
Emerging Risk Factors Collaboration (Di Angelantonio et al., 2012)
Adding emerging lipid markers (apoB, Lp(a), Lp‑PLA2) to total cholesterol and HDL‑C did not significantly improve CVD risk prediction in large pooled cohorts.
Lp(a) — stroke recurrence (Palaiodimou et al., 2025)
Elevated Lp(a) associated with increased stroke recurrence (OR 1.69) and poor functional outcome (OR 2.09); clinical utility to change management not established.
Berman et al. (2024) Lp(a)
Adjusted HRs: 1.21 (71st–90th pct) and 1.26 (91st–100th pct) for MACEs in patients with baseline ASCVD; measurement did not address impact on outcomes.
BiomarCaRE (Waldeyer et al. 2017)
HR 1.30 for MCEs (67th–89th pct) and HR 1.49 (>90th pct) vs lowest third — elevated Lp(a) associated with greater risk in population cohorts.
Lp‑PLA2 meta‑analyses (Hu et al. 2019; Li et al. 2017a; Tian et al. 2017)
Elevated Lp‑PLA2 mass/activity associated with modestly increased risk of stroke and CHD (RRs per SD ≈1.07–1.11; highest vs lowest up to ~1.56); heterogeneity and low overall quality limit clinical utility.
Multiprotein panels (Neumann 2024; McCarthy 2020; Mohebi 2023; Hayes 2023 brief)
Multiprotein biomarker scores are associated with outcomes and report AUCs (eg, models AUC ~0.77–0.86 in derivation/validation), but studies do not demonstrate improved clinical management or outcomes and clinical utility is insufficient.
Endothelial function studies (Cooper 2021; Schnabel 2021; Venuraju 2019)
PAT/flow‑mediated dilation show inconsistent associations with composite CVD events (not predictive in multivariable models); PAT associated with stroke in some analyses but routine use not supported.
Key guideline sources (ACC/AHA, AHA, NLA, ESC/EAS, AACE/AACE updates, ADA)
Guidelines broadly do not endorse routine use of arterial compliance, CIMT, advanced lipoprotein testing or PAT for population screening; many recommend selective Lp(a)/apoB measurement in specified scenarios and cite thresholds (eg, Lp(a) ≥50 mg/dL as risk‑enhancing).

Applicable Codes

Specific Proprietary/PLA Codes Referenced (related services)mixed

0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations.
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation.
0308U	Cardiology (CAD), analysis of 3 proteins (hs-troponin, adiponectin, KIM-1) with 3 clinical parameters, plasma, algorithm reported as a risk score for obstructive CAD.
0309U	Cardiology (CVD), analysis of 4 proteins (NT-proBNP, osteopontin, TIMP-1, KIM-1), plasma, algorithm reported as a risk score for major adverse cardiac event.
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by NMR spectrometry with report of a lipoprotein profile (including 23 variables).
0415U	Cardiovascular disease (ACS), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year score for ACS.
0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins, serum, algorithm reported as prediction of coronary artery disease (pCAD) score.
83695	Lipoprotein (a).
83698
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including subclasses.

1–10 of 15

1/2

Provider Actions and Billing Notes

Denial Risk

Not medically necessary — testing

Testing for the listed advanced cardiovascular risk tests is considered not medically necessary due to insufficient evidence of clinical efficacy. Claims for these tests may be denied when submitted for routine screening or risk stratification outside guideline-endorsed indications.

83695
0052U
0377U
0415U
0541U
0308U
0309U
0019M

Documentation Required

Definitions

Term	Definition
CIMT
Carotid intima-media thickness measurement using ultrasound to assess carotid artery wall thickness.
Lp-PLA2
Lipoprotein-associated phospholipase A2, a vascular inflammatory enzyme investigated as a biomarker for coronary heart disease and stroke risk.
ePWV/cfPWV
Estimated or carotid‑femoral pulse wave velocity, measures of arterial stiffness.
MACE / MACEs
Major adverse cardiovascular events, commonly including myocardial infarction, coronary revascularization, stroke, or cardiovascular death.
PAT
Peripheral arterial tonometry, a fingertip-based measure of microvascular function (pulse amplitude/reactive hyperemia index).
CEC
Cholesterol efflux capacity, a measure of HDL functionality assessing reverse cholesterol transport.
PAT (Peripheral Arterial Tonometry)
A noninvasive fingertip measurement of pulse amplitude/reactive hyperemia intended to assess digital microvascular function (RHI and PAT ratio).
RHI (Reactive Hyperemia Index)
A derived index from PAT representing reactive hyperemic response; used to infer endothelial function.
Lp(a)
Lipoprotein(a), an LDL-like particle associated with genetic risk for ASCVD and aortic valve stenosis; used as a risk‑enhancing biomarker.
apoB
Apolipoprotein B, a measure of atherogenic particle number; considered useful for risk assessment when discordant with LDL-C.

Referenced Thresholds

Exact numeric thresholds (preserved from sources)

Lp(a) — NLA/ESC/ACC/AHA thresholdsLow < 75 nmol/L (≈ 30 mg/dL); intermediate 75–125 nmol/L (30–50 mg/dL); high ≥ 125 nmol/L (50 mg/dL). ACC/AHA: Lp(a) ≥ 50 mg/dL (≥ 125 nmol/L) is risk‑enhancing; ESC/EAS: consider > 50 mg/dL (≥ 105 nmol/L) to refine risk; ESC flags very high inherited Lp(a) > 180 mg/dL (> 430 nmol/L)

Lp(a) — study/registry cutoffsATTICA used 50 mg/dL as abnormal; BiomarCaRE reports risk increases in 67th–89th and > 90th percentiles

apoB thresholds (AACE/NLA/ACC contexts)AACE/NLA: goal < 90 mg/dL for increased ASCVD risk; < 80 mg/dL for established ASCVD or diabetes + risk factor; < 70 mg/dL for extreme risk. ACC/AHA: apoB ≥ 130 mg/dL is risk‑enhancing

hs‑CRP (ACC/AHA)≥ 2.0 mg/L considered a risk‑enhancing factor

Primary hypertriglyceridemia (ACC/AHA)≥ 175 mg/dL (nonfasting) is a risk‑enhancing factor

NT‑proBNP / BNP (ADA)

Revision History

2026-05-01revisedLatest

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information. Archived previous policy version CS015KS.02.